4 completed, 1 withdrawn. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
Follow Foretinib: new trials by email Literature Review of Foretinib trials Research Report on Foretinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer Foretinib, Erlotinib - Cancer | Phase 2 | Withdrawn | GlaxoSmithKline | 2014-04-01 | 2014-05-19 | |
| Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer Foretinib, Lapatinib - Breast Cancer | Phase 1 / Phase 2 | Completed | NCIC Clinical Trials Group | 19 | 2010-10-27 | 2023-08-04 |
| A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer Foretinib - Recurrent Breast Cancer | Phase 2 | Completed | NCIC Clinical Trials Group | 47 | 2010-09-02 | 2023-08-04 |
| Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer Foretinib - Carcinoma, Hepatocellular | Phase 1 | Completed | GlaxoSmithKline | 45 | 2009-08-12 | 2017-07-18 |
| Study of GSK1363089 in Metastatic Gastric Cancer GSK1363089 (formerly XL880) - Neoplasms, Gastrointestinal Tract | Phase 2 | Completed | GlaxoSmithKline | 74 | 2007-03-31 | 2017-08-24 |
Breast Neoplasms (2) · Neoplasms (2) · Adenocarcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Stomach Neoplasms (1)
GlaxoSmithKline (3) · NCIC Clinical Trials Group (2)
Canada (2) · Hong Kong (1) · Taiwan (1) · Thailand (1) · United States (1)
Daniel Rayson (1) · Sasha Lupichuk (1) · Stephen Chia (1)